Your institution may have access to this item. Find your institution then sign in to continue.
Title
Rarefied drug pricing.
Abstract
The author discusses the challenges of drug development and pricing. Topics discussed include the difficulty faced by drug manufacturer Alexion Pharmaceuticals in developing and pricing the Solaris (eculizumab) drug, the enactment of the U.S. Orphan Drug Act in 1983, and the need for the drug development industry to alter its way of accounting and auditing reaseach and development (R&D) to comply with the requirements of the National Center for Clinical Excellence (NICE).